Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple extracted claims about clinical signs (e.g., dark urine, nausea/vomiting, abdominal pain, bruising/confusion) and several management nuances (e.g., rechallenge strategy, alternative diagnosis differential, expected recovery window, specialist/urgent care, imaging) are not supported by the provided FDA label excerpt (primarily 5.2). Core label-consistent points (monitoring, dose reduction/withdrawal leading to near baseline without sequelae, jaundice mention, alcohol cautions) are present, but overall label overreach reduces adherence.
Category Scores
Accurate Statements
When statin-related liver injury is identified, stopping the drug or adjusting the dose leads to liver enzyme levels returning to or near pretreatment levels without sequelae (with monitoring).
5.2 Liver Dysfunction: 'Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae' and 'Patients who develop increased transaminase levels should be monitored until the abnormalities resolve.'
Signs of significant liver injury include jaundice (yellowing of the skin/eyes).
5.2 Liver Dysfunction: 'One patient in clinical trials developed jaundice... Increases in liver function tests... were not associated with jaundice...' (establishes jaundice association).
The key step in managing statin liver injury is identifying and removing the trigger, including stopping Lipitor if advised.
5.2 Liver Dysfunction: 'Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of LIPITOR is recommended.'
Clinicians should monitor liver function tests prior to therapy and at 12 weeks following initiation and after any elevation of dose, and periodically thereafter; patients with increased transaminases should be monitored until resolution.
5.2 Liver Dysfunction and 17.2 Liver Enzymes: 'performed prior to and at 12 weeks following both the initiation... and any elevation of dose, and periodically (e.g., semiannually) thereafter' and 'Patients who develop increased transaminase levels should be monitored until the abnormalities resolve.'
Clinicians review alcohol intake when evaluating liver test abnormalities.
5.2 Liver Dysfunction: 'LIPITOR should be used with caution in patients who consume substantial quantities of alcohol...'
Unsupported Statements
Serious permanent liver injury from statins is uncommon.
Not explicitly stated in the provided label excerpt (5.2).
Mild lab abnormalities (elevated liver enzymes) often improve after stopping Lipitor and may normalize without lasting damage.
5.2 supports return of transaminases to or near pretreatment levels without sequelae, but the 'often'/'may normalize without lasting damage' phrasing is not explicitly verifiable as written from the excerpt.
Statin-related hepatitis/injury can still improve and resolve, especially once the offending drug is discontinued early.
5.2 discusses transaminase return without sequelae and monitoring, but 'hepatitis/injury' and the 'especially once...discontinued early' nuance is not explicitly supported.
Severe injury leading to liver failure from statins is rare.
Not explicitly stated in the provided label excerpt (5.2).
If severe liver failure occurs, recovery may be incomplete and requires urgent specialist care.
Not explicitly supported in the provided label excerpt (5.2).
Signs of significant liver injury include dark urine.
Not present in the provided label excerpt (5.2).
Signs of significant liver injury include severe fatigue and nausea/vomiting.
Not present in the provided label excerpt (5.2).
Signs of significant liver injury include right upper abdominal pain.
Not present in the provided label excerpt (5.2).
Signs of significant liver injury include easy bruising or confusion.
Not present in the provided label excerpt (5.2).
Improvement for most statin-associated liver test elevations is seen after the drug is withdrawn with monitoring until levels trend down.
5.2 supports return to near pretreatment levels without sequelae and monitoring until resolution, but does not explicitly support 'most' or 'trend down' wording/quantification.
Persistent abnormalities beyond the expected recovery window may require further evaluation for other causes such as viral hepatitis, fatty liver disease, alcohol-related liver injury, medication interactions, or bile duct problems.
The provided label excerpt does not enumerate alternative etiologies or reference an 'expected recovery window' framing.
If the initial liver reaction was mild and reversible, clinicians sometimes consider restarting Lipitor at a lower dose or switching to a different statin with close monitoring.
5.2 supports dose reduction/reduction or continued treatment with reduced dose in a subset, but the specific rechallenge/switching guidance is not explicitly stated in the excerpt.
If the injury was severe or there was concern for true hepatitis, clinicians may avoid rechallenge and choose other lipid-lowering options.
Not explicitly supported in the provided label excerpt (5.2).
After abnormal liver tests or symptoms, clinicians generally repeat liver blood tests, commonly ALT, AST, and bilirubin, and check whether values are falling.
5.2 supports monitoring and mentions ALT/AST thresholds, but the explicit inclusion of 'bilirubin,' and 'generally'/'values are falling' is not supported in the provided excerpt.
Clinicians also review other medicines/supplements that may affect the liver when evaluating liver test abnormalities.
Not present in the provided label excerpt (5.2).
Clinicians evaluate symptoms and physical exam findings when liver test abnormalities occur.
5.2 discusses clinical signs/symptoms being absent in many cases, but does not explicitly support this general evaluation statement.
If abnormalities don’t improve as expected, additional tests and imaging may be needed.
Not supported by the provided label excerpt.
There is no specific antidote for statin liver injury.
The provided label excerpt for liver dysfunction does not state 'no specific antidote.' (10 OVERDOSAGE discusses no specific treatment for overdose, not a liver-injury antidote claim.)
Management of complications of severe statin liver injury is done by a specialist.
Not supported by the provided label excerpt (5.2).
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The label’s specific monitoring schedule details (prior to therapy; at 12 weeks after initiation; and after dose increases; periodic semiannually thereafter) are not included in the extracted claims set, except partially via general 'repeat labs/monitor until resolution' statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported symptom lists and management nuances could mislead users about which signs matter and what steps are label-supported, even though the excerpt does support dose reduction/withdrawal and monitoring until resolution.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims are explicitly not supported by the provided FDA label excerpt (mostly 5.2), especially detailed symptom descriptions, alternative differential/expected recovery framing, and rechallenge/specialist/urgent care guidance.
Suggested Improvement
Restrict claims to what is in 5.2/17.2: transaminase biochemical abnormalities, monitoring schedule, threshold prompting dose reduction/withdrawal, and that transaminases return to near pretreatment levels without sequelae upon dose reduction/interrupt/discontinuation; avoid adding unsupported symptom lists or rechallenge/specialist/antidote statements.